Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer

NCT00217711 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00217711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00217711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2005
Completion date
October 31, 2011
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer